---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-216699"
form_type: "8-K"
ticker: "COAG"
cik: "0002114044"
company_name: "Hemab Therapeutics Holdings, Inc."
filed_at: "2026-05-11T20:01:15+00:00"
generated_at: "2026-05-11T20:03:14.867339+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Director Laura Tadvalkar resigns from Hemab Therapeutics board effective May 8, 2026

## Summary
- Laura Tadvalkar, Ph.D., resigned as a member of the Board, effective May 8, 2026.
- Resignation not related to any disagreement with the Company on operations, policies or practices.
- No replacement director announced; Board size reduced by one.

## SEC filing metadata
- accession: 0001193125-26-216699
- form_type: 8-K
- ticker: COAG
- cik: 0002114044
- company_name: Hemab Therapeutics Holdings, Inc.
- filed_at: 2026-05-11T20:01:15+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2114044/000119312526216699/0001193125-26-216699-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2114044/000119312526216699/d141757d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-216699
- JSON: https://secwatch.observer/filing/0001193125-26-216699.json
- Plain text: https://secwatch.observer/filing/0001193125-26-216699.txt

## Key facts
- Executive change
  Laura Tadvalkar resigned as Director at Hemab Therapeutics Holdings, Inc..
  - Action: resigned
  - Role: Director
  source text: On May 8, 2026, Laura Tadvalkar, Ph.D., notified Hemab Therapeutics Holdings, Inc. (the “Company”) of her decision to resign as a member of the Company’s board of directors (the “Board”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2114044/000119312526216699/0001193125-26-216699-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.